VRAX (Virax Biolabs Group) Debt-to-EBITDA : -0.06 (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Virax Biolabs Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.09 Mil. Virax Biolabs Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.29 Mil. Virax Biolabs Group's annualized EBITDA for the quarter that ended in Mar. 2025 was $-6.19 Mil. Virax Biolabs Group's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 was -0.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Virax Biolabs Group's Debt-to-EBITDA or its related term are showing as below:

VRAX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.07 Med: -0.03 Max: -0.03
Current: -0.07

During the past 6 years, the highest Debt-to-EBITDA Ratio of Virax Biolabs Group was -0.03. The lowest was -0.07. And the median was -0.03.

VRAX's Debt-to-EBITDA is ranked worse than
100% of 293 companies
in the Biotechnology industry
Industry Median: 1.15 vs VRAX: -0.07

Virax Biolabs Group Debt-to-EBITDA Historical Data

The historical data trend for Virax Biolabs Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Debt-to-EBITDA Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.03

-0.07

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25
Debt-to-EBITDA	Get a 7-Day Free Trial						-0.02	-0.03	-0.03	-0.07	-0.06

Competitive Comparison of Virax Biolabs Group's Debt-to-EBITDA

For the Biotechnology subindustry, Virax Biolabs Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Debt-to-EBITDA falls into.

Save Embed

;

Save Embed

;

Virax Biolabs Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Virax Biolabs Group's Debt-to-EBITDA for the fiscal year that ended in Mar. 2025 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.085	+	0.292)	/	-5.802
	=	-0.06

Virax Biolabs Group's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.085	+	0.292)	/	-6.186
	=	-0.06

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Mar. 2025) EBITDA data.

Virax Biolabs Group (NAS:VRAX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Virax Biolabs Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.